Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Pembrolizumab, sold under the brand name Keytruda, is a humanized monoclonal antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy to treat many types of cancer. It is administered by slow intravenous injection.
The analysis highlights History, Community, Culture and Applications as prominent areas in the source structure around Pembrolizumab.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
The extracted context around Pembrolizumab shows recurring relationship patterns in the source. For example, Pembrolizumab → As, Bristol Myers Squibb, Co, Eenennaam, Foundation, Gradus Dulos, Hans, He, In, IND, Intellectual Property Owners Education, Inventors, Inventors Gregory Carven, Later, LifeArc, Martin Huber, Medical Research Council Technology, Medicine, Merck, Opdivo Another extracted example is Pembrolizumab → As, At ASCO, IB, II, In, June, Keynote-012, Keynote-086, May, Merck, TNBC. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
metastatic cancer treatment fda approved us pd-l1 advanced carcinoma cell people chemotherapy tumors trial combination adults drug lung locally participants
TTTA extracted 113 structured relationships around Pembrolizumab. Examples in this analysis include Pembrolizumab → AHFS/Drugs.com → Monograph and Pembrolizumab → ATC code → L01FF02 (WHO). The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Pembrolizumab | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Pembrolizumab | ATC code | L01FF02 (WHO) | 1.00 | infobox |
| Pembrolizumab | CAS Number | 1374853-91-4 | 1.00 | infobox |
| Pembrolizumab | ChEMBL | ChEMBL3137343 | 1.00 | infobox |
| Pembrolizumab | ChemSpider | none | 1.00 | infobox |
| Pembrolizumab | Drug class | Antineoplastic | 1.00 | infobox |
| Pembrolizumab | DrugBank | DB09037 | 1.00 | infobox |
| Pembrolizumab | ECHA InfoCard | 100.234.370 | 1.00 | infobox |
| Pembrolizumab | Formula | C6534H10004N1716O2036S46 | 1.00 | infobox |
| Pembrolizumab | KEGG | D10574 | 1.00 | infobox |
| Pembrolizumab | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Pembrolizumab | Legal status | CA: ℞-only / Schedule D | 1.00 | infobox |
| Pembrolizumab | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Pembrolizumab | Legal status | US: ℞-only | 1.00 | infobox |
| Pembrolizumab | Legal status | EU: Rx-only | 1.00 | infobox |
| Pembrolizumab | Legal status | In general: ℞ (Prescription only) | 1.00 | infobox |
| Pembrolizumab | License data | US DailyMed: Pembrolizumab | 1.00 | infobox |
| Pembrolizumab | MedlinePlus | a614048 | 1.00 | infobox |
| Pembrolizumab | Molar mass | 146648.64 g·mol−1 | 1.00 | infobox |
| Pembrolizumab | Other names | MK-3475, lambrolizumab | 1.00 | infobox |
| Pembrolizumab | Pregnancy category | AU: D | 1.00 | infobox |
| Pembrolizumab | Routes of administration | Intravenous | 1.00 | infobox |
| Pembrolizumab | Source | Humanized (from mouse) | 1.00 | infobox |
| Pembrolizumab | Target | PD-1 | 1.00 | infobox |
| Pembrolizumab | Trade names | Keytruda | 1.00 | infobox |
| Pembrolizumab | Type | Whole antibody | 1.00 | infobox |
| Pembrolizumab | UNII | DPT0O3T46P | 1.00 | infobox |
| Pembrolizumab | is a | so-called tissue-agnostic drug.In the European Union | 0.90 | text |
The concept neighborhoods around Pembrolizumab bring nearby vocabulary together. In this analysis, examples include Fda, Us and Treatment. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Pembrolizumab, one of the stronger structural bridges in this analysis connects Pembrolizumab with Medical uses. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Pembrolizumab to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as History, Community, Culture & Applications, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Pembrolizumab · EN edition · Analysis: TopicsToTalkAbout